Experimental versus Observational Data in the Economic Evaluation of Pharmaceuticals

Mark D. , Hlatky MA , Califf RM , et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418-24.

Kassirer JP , Angel M. The Journal's policy on cost-effectiveness analyses (editorial. N Engl J Med. 1994;331:669-70.

Food and Drug Administration. Principles for the Review of Pharmacoeconomic Promotion (Draft. Rockville, MD, 1995.

Commonwealth of Australia. Department of Health Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra , Australia: Australian Government Publishing Service , 1995.

Rittenhouse BE , O'Brien BJ Threats to the validity of pharmacoeconomic analyses based on clinical trial data. In Spilker B (ed). Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia, PA: Lippincott-Raven , 1996.

Drummond MF , Davies LM Economic analysis alongside clinical trials: revising the methodological issues . Int J Technol Assess Health Care. 1991;7:561-73.

Oster G. , Borok G. , Menzin J. , et al. A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS. Controlled Clinical Trials. 1995;16:3-16.

O'Brien BJ , Anderson D. , Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep vein thrombosis after total hip replacement. Can Med Assoc J. 1994;150:1083-172.

O'Brien BJ , Goeree R. , Mohamed AH , Hunt R. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med. 1995;155:1958-64.

Drummond MF , O'Brien BJ , Stoddart GL , Torrance GW Methods for the Economic Evaluation of Health Care Programmes. Oxford, U.K.: Oxford University Press, 1997.

EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein Iib/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-61.

Sheldon TA Problems of using modelling in the economic evaluation of health care. Health Econ. 1996;5:1-11.

Schulman KA , Kinosian B. , Jacobson JA , et al. Reducing high blood cholesterol level with drugs. JAMA. 1990;264:3025-33.

Mason JM , Drummond MF , Torrance GW Some guidelines on the use of cost-effectiveness league tables. Br M J. 1993; 306:570-2.

Freemantle N. , Drummond MF Should clinical trials with concurrent economic analyses be blinded? JAMA. 1997;227: 63-4.

Ellwein L. , Drummond MF Economic analysis alongside clinical trials: bias in the measurement of economic outcomes. Int J Technol Assess Health Care. 1996;12:691-7.

Gold MR , Siegel JE , Russell LB , Weinstein MC (eds). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.

Feeny D. , Furlong W. , Boyle M. , Torrance GW Multiattribute health status classification systems: Health Utilities Index . PharmacoEconomics. 1995;7:490-502.

Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B (ed). Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia, PA: Lippincott-Raven, 1996.

Schwartz, D. , Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis. 1967;20:63-4.